Evidence map›Paper›PMID 41658607›Full record

ArticleFrontiers in medicine2026

Pregnancy outcomes of patients with retained products of conception following miscarriage treated with relugolix, an oral gonadotropin-releasing hormone antagonist.

Satoko Sasatsu, Yosuke Ono, Dai Miyashita, Tatsuya Yoshihara, Kota Tanaka, Yuri Tada, So Owada, Akiko Nakagomi, Shoko Ikeda, Maki Ohgi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Satoko Sasatsu *Department of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Yosuke Ono *Department of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Dai MiyashitaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Tatsuya YoshiharaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Kota TanakaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Yuri TadaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
So OwadaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Akiko NakagomiDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Shoko IkedaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Maki OhgiDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Eriko OgasaharaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Hikaru TagayaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Yasuhiko OkudaDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.
Osamu YoshinoDepartment of Obstetrics and Gynecology, University of Yamanashi, Chuo City, Yamanashi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Relugolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, represents a potentially effective and less invasive therapeutic approach for retained products of conception (RPOC). However, its impact on subsequent pregnancy outcomes remains unclear. This study aimed to evaluate these outcomes following GnRH antagonist treatment for RPOC. Methods: This single-center cohort study encompassed 20 patients diagnosed with RPOC following miscarriage or abortion before 22 gestational weeks who were treated with oral relugolix, a GnRH antagonist, from January 2022 to July 2024. Following treatment completion and hysteroscopic confirmation of complete resolution, 12 patients subsequently conceived and were prospectively followed for pregnancy and neonatal outcomes. To contextualize outcomes, results were compared with the non-GnRH antagonist group managed at the same institution from 2014 to 2021 without GnRH antagonist exposure. Results: The GnRH antagonist group had fewer patients requiring surgical intervention than the non-GnRH antagonist group [30.0% (6/20) vs. 70.1% (54/77), Conclusion: Relugolix therapy for RPOC was associated with preserved fertility and favorable pregnancy outcomes comparable to conventional management.

Indexed as

assisted reproductive technologyGnRH antagonistpregnancy outcomerelugolixretained products of conception

Identifiers

PMID41658607
PMCPMC12876250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.